Clinical Oncology 종합 리뷰

category

overviews

개요

본 리뷰는 LLM Wiki "Clinical Oncology" 카테고리에서 추출된 117편의 논문 기반 핵심 노트를 종합하여, 비소세포폐암(NSCLC) 및 두경부암(HNSCC) 등 고형암의 최신 치료 전략, 예후 인자, 그리고 면역항암제(Immunotherapy)의 임상 적용 현황을 분석한다. 주요 경향으로는 수술 불가능한 Stage III NSCLC 환자에서 Consolidation Immunotherapy(Durvalumab)의 표준화 및 Real-world 효능 검증, 재수술 가능한 NSCLC에서 Neoadjuvant Chemoimmunotherapy의 병리적 반응(pCR/MPR) 및 생존 이점 입증, 그리고 EGFR 변이성 폐암에서의 Osimertinib 보조 요법(ADAURA trial)의 확립이 두드러진다. 또한, 종양 이질성(Heterogeneity), 면역 미세환경(TME) 분석, 그리고 AI 기반 영상 및 조직학적 예측 모델의 발전이 정밀의학(Precision Medicine) 접근을 뒷받침하고 있다.

주요 주제

Stage III NSCLC에서의 Consolidation Immunotherapy 및 Real-world 적용 PACIFIC trial은 Definitive chemoradiotherapy (CRT) 후 Durvalumab을 Consolidation therapy로 사용할 경우, Placebo군 대비 Progression-free survival (PFS)과 Overall survival (OS) 모두에서 통계적으로 유의미한 우월성을 입증했다 [5][6]. 특히 PD-L1 high (≥50%) 환자군에서 생존 이점이 뚜렷하며 [21], PACIFIC trial subgroup analysis에서도 모든 PD-L1 서브그룹에서 PFS 개선 효과가 확인되었고 TC ≥25% 그룹에서 가장 큰 효과(HR 0.41)를 보였다 [73]. Real-world data(SPOTLIGHT study, PACIFIC-KR 등)는 일상 임상 환경에서도 이러한 효능이 유지됨을 시사하며 [62][72], nationwide claims database 분석에서는 median OS가 48.4개월로 trial 결과와 유사함을 확인했다 [100][101]. 그러나 치료 중단률(Attrition)이 높게 나타나, Treatment duration de-escalation (6~9개월)의 타당성 평가 및 조기 중단 원인(Disease progression, Lung toxicity) 규명이 중요한 과제로 대두되었다 [10][11][74].

Neoadjuvant Immunotherapy의 효능 및 반응 예측 재수술 가능한 NSCLC 환자에서 Neoadjuvant chemoimmunotherapy는 Chemotherapy alone 대비 Major pathological response (MPR), Pathologic complete response (pCR), Event-free survival (EFS), 그리고 Overall survival (OS)에서 유의미한 우위를 보였다 [22][23][92][114]. CheckMate 816 trial에서는 Nivolumab plus chemotherapy가 Chemotherapy alone 대비 EFS와 pCR을 개선하며, 장기 OS 향상(5-year OS: 65.4% vs 55.0%)으로 이어짐을 입증했다 [22][23]. 특히 Lung squamous cell carcinoma (LUSC) 하위군에서 더 높은 병리적 반응을 나타냈다 [114]. 반응 예측을 위해 Dynamic 18F-FDG PET/CT의 SUVmax 감소율(≥60%)이 MPR 예측의 독립적 인자로 확인되었으며 [13], Chest CT 기반 Deep learning 모델(DL score) 및 ctDNA monitoring, TCR repertoire sequencing 등이 기존 단일 지표보다 우수한 예측력을 보일 수 있음이 제시되었다 [88][107].

EGFR 변이성 NSCLC의 치료 전략: Adjuvant Osimertinib vs. Consolidation Immunotherapy 수술 후 EGFR 변이성 Stage IB~IIIA NSCLC 환자에서 ADAURA trial은 Osimertinib 보조 요법이 Placebo 대비 유의한 OS 이점(HR 0.49)을 입증하여 표준 치료로 자리 잡았다 [104][109]. 반면, 수술 불가능한 Stage III EGFR-mutated NSCLC 환자에서는 LAURA trial이 Definitive CRT 후 Osimertinib 투여가 Placebo 대비 median PFS를 39.1개월 대 5.6개월로 유의하게 연장시켰음을 보여주었다 [59]. 이에 반해 PACIFIC trial의 post hoc subgroup analysis는 Stage III EGFR-mutant 환자에서 Consolidation Durvalumab이 Placebo 대비 PFS 이점을 보이지 않았음을 시사한다 (median PFS: 11.2개월 vs 10.9개월) [64]. 이는 Driver mutation 보유 환자군에서 Targeted therapy와 Immunotherapy의 선택에 있어 명확한 차별화가 필요함을 의미한다.

종양 이질성(Heterogeneity) 및 면역치료 저항성 기전 종양 내 이질성(Intratumor Heterogeneity, ITH)은 치료 반응과 저항성에 중요한 영향을 미친다. Lung adenocarcinoma에서 Primary tumor와 Metastatic sites 간 Immunogenomic intertumor heterogeneity 분석 결과, Clonal TP53 mutation은 초기 사건이었으나 다른 Somatic mutations과 Immune landscape는 공간적 이질성을 보였다 [12]. Pembrolizumab monotherapy 중 Radiologic progression 시 Lesion-level heterogeneity가 관찰되어, Primary progression 환자의 51-63%가 Growing, Stable, Shrinking lesions이 혼합된 Mixed response pattern을 보였다 [102]. 또한 dMMR/MSI 종양에서도 ITH는 Immune selection pressure 하에서 Resistant subclone의 선택적 증식을 야기하여 치료 저항성을 유발한다 [110]. Metastatic niche 형성 기전으로는 원발성 종양의 Soluble factors와 Extracellular vesicles(EVs)이 원격 장기의 미세환경을 변화시켜 Pre-metastatic niche(PMN)을 형성하는 것으로 규명되었다 [76].

면역치료 관련 폐독성(Immune-related Pneumonitis) 및 예측 인자 Checkpoint inhibitor pneumonitis (CIP) 또는 Radiation pneumonitis (RP)는 Immunotherapy 중 주요한 Immune-related adverse events (irAEs)이다. LA-NSCLC 환자에서 CCRT 후 Durvalumab 투여 시 Grade ≥2 RP 발생률은 36%였으며, Lung dose-volume parameter 중 V30이 RP 발생과 유의한 상관관계를 보였다 [85]. Real-world 연구에서는 Any grade pneumonitis 발생률이 83%로 보고되었으며, Symptomatic pneumonitis (≥ Grade 2)도 빈번하게 발생했다 [86]. Baseline derived neutrophil-to-lymphocyte ratio (dNLR)는 CIP 및 irAEs 발생 위험을 예측하는 Biomarker로 유용성이 확인되었고 [96], 치료 전 DLCO 수준과 방사선 선량학 파라미터(V65–45%)도 폐독성 위험 평가에 중요한 지표이다 [94].

두경부암(HNSCC)의 예후 인자 및 병기 분류 진화 HNSCC에서 Pathological Extranodal Extension (pENE)는 Aggressive tumor phenotype, Locoregional recurrence, Distant metastasis 및 Reduced overall survival (OS)과 연관된 핵심 Prognostic biomarker이며, AJCC 8th edition 및 UICC 9th edition(2025) 병기 체계 변경의 배경이 되었다 [15]. Radiologic ENE는 OS의 독립적인 불량 예후 인자이며, Pathologic ENE 예측에는 Sensitivity는 낮으나 Specificity가 매우 높게 나타났다 [40][41]. 또한 NPC에서는 PD-L1 발현이 Clinical Stage 및 N classification과 연관이 있으며, Tumor-Associated Macrophage (TAMs) 침윤 밀도가 높을수록 PD-L1 발현 증가와 통계적 유의성을 보였다 [17].

방법론적 경향

연구 설계 및 Cohort 특징 본 리뷰에 포함된 연구들은 Randomized controlled trials (PACIFIC, CheckMate 816, ADAURA, LAURA 등)과 Retrospective cohort studies, Meta-analyses가 혼재되어 있다. Real-world evidence (RWE) 연구들이 증가하여, 임상 시험의 엄격한 포함 기준(Inclusion criteria)을 충족하지 못하는 환자군(예: PACIFIC trial inclusion criteria 미충족 환자 [45], VHA nationwide cohort [63])에서의 치료 결과와 안전성을 평가하는 경향이 강하다. 특히 Stage III NSCLC에서 Durvalumab의 Real-world 적용 패턴과 Attrition rate를 분석한 연구들이 다수 포함되었다 [62][74].

Endpoint 및 통계적 분석 전통적인 Overall survival (OS)과 Progression-free survival (PFS) 외에도, Pathologic complete response (pCR), Major pathological response (MPR), Event-free survival (EFS)가 Neoadjuvant setting에서 중요한 Surrogate endpoint로 활용되고 있다 [18][22]. 또한, Disease-free survival (DFS)와 Recurrence-free survival (RFS)도 Early-stage NSCLC 수술 후 예후 평가에 광범위하게 사용된다 [75][77]. 통계적 방법론에서는 Propensity-score matching [91], Recursive partitioning and amalgamation algorithm [29], 그리고 Machine learning 기반 예측 모델(XGBoost, Deep learning, Random Forest)의 적용이 두드러진다 [26][88][103].

Biomarker 및 영상 진단 기술 PD-L1 IHC Assay (22C3, 28-8, SP263, SP142) 간의 비교 및 표준화 연구가 진행되었으며, Tumor cell (TC) 염색 패턴의 유사성과 Immune cell (IC) 염색의 차이를 분석했다 [38][50]. 영상 진단 측면에서는 RECIST 1.1 기준의 한계를 보완하기 위해 wsPERCIST 판독 기준 제안 [60], PET/CT의 SUVmax 감소율 활용 [13], 그리고 AI 기반 WSI 분석(Lunit SCOPE IO)을 통한 Immune phenotype (Inflamed, Immune-excluded, Immune-desert) 분류가 시도되었다 [71]. 또한, ctDNA 및 ctA (Circulating tumor antigen) 패널을 이용한 Minimal residual disease (MRD) 모니터링과 치료 반응 예측이 활발히 연구되고 있다 [42][103][107].

임상적·연구적 시사점

치료 알고리즘의 정교화와 개인화 NSCLC 치료는 Driver mutation 유무와 병기에 따라 명확히 분화되고 있다. EGFR/ALK 변이성 환자에서는 Targeted therapy (Osimertinib 등)가 1st-line 및 Adjuvant setting에서 표준이며 [81][82][104], Wild-type 환자에서는 Immunotherapy 기반 요법(Chemoimmunotherapy 또는 Monotherapy)이 주류이다. 특히 Stage III Unresectable NSCLC에서 Durvalumab Consolidation therapy는 표준 치료로 자리 잡았으나, 폐독성(RP/CIP) 관리와 치료 지속 기간 최적화가 임상적 도전 과제로 남아있다 [5][6][85].

면역치료의 안전성 관리 및 예측 모델 필요성 Immunotherapy 관련 폐독성은 치료 중단과 생존율 저하의 주요 원인이다. 방사선 선량학 파라미터(V30, V5Gy 등)와 Baseline dNLR, DLCO 등을 통합한 위험 평가 모델의 개발이 시급하다 [85][94][96]. 또한, Hyperprogressive Disease (HYD)와 Pseudoprogression과 같은 Atypical response patterns에 대한 표준화된 정의와 평가 기준(wsPERCIST 등) 마련이 치료 전략 수정에 필수적이다 [9][20][60].

종양 이질성과 미세환경의 임상적 통합 종양 내 및 종양 간 이질성(Heterogeneity)은 치료 반응과 저항성의 핵심 기전이다. Tumor microenvironment (TME) 분석, 특히 TILs, TAMs, PD-L1/PD-L2 발현 패턴을 이해하는 것은 Immunotherapy 반응 예측에 중요하다 [78][97]. 향후 연구에서는 Radiomics, Genomics, Pathology 데이터를 통합한 Multimodal Machine learning 모델(DyAM, TEMPO-HCC 등)을 통해 더 정교한 예후 예측과 치료 반응을 모니터링하는 방향으로 발전할 것으로 보인다 [30][54][103].

남은 Gap 및 향후 방향 Neoadjuvant setting에서 Neoadjuvant-only vs. Perioperative (Neoadjuvant + Adjuvant) 요법의 생존 이점 차이가 명확하지 않아, 최적의 치료 기간과 조합에 대한 추가 연구가 필요하다 [116]. 또한, Real-world setting에서의 Treatment attrition rate를 낮추기 위한 전략(예: Dose de-escalation, Toxicity management guideline 개선)이 요구된다 [10][11][74]. 마지막으로, EGFR 변이성 Stage III NSCLC에서 Immunotherapy의 역할은 여전히 제한적이며, Targeted therapy와 Immunotherapy의 병용 또는 순차 요법에 대한 고위험군 대상 연구가 필요하다 [59][64].

참고 논문

1. Sublobar resection, stereotactic body radiotherapy, and thermal ablation for early-stage non-small cell lung cancer a systematic review and meta-analysis — Adar et al., 2026, Lung Cancer
2. Recurrence Risk Following Percutaneous Transthoracic Needle Biopsy in Patients Undergoing Sublobar Resection for Stage I Lung Cancer — Ahn et al., 2025, Radiology
3. The Eighth Edition AJCC Cancer Staging Manual Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging — Amin et al., 2017, CA Cancer J Clin
4. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging — Amin et al., 2017, CA: A Cancer Journal for Clinicians
5. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer — Antonia et al., 2017, The New England Journal of Medicine
6. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC — Antonia et al., 2018, The New England Journal of Medicine
7. The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types — Awada et al., 2025, Nature Cancer
8. Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase 2 Trial — Bang et al., 2025, Journal of Thoracic Oncology
9. Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth? — Britt et al., 2022, Frontiers in Oncology
10. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer — Bryant et al., 2022, European Journal of Cancer
11. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer — Bryant et al., 2022, European Journal of Cancer
12. Immunogenomic Intertumor Heterogeneity Across Primary and Metastatic Sites in a Patient With Lung Adenocarcinoma — Chen et al., 2021
13. Dynamic (18) F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer — Chen et al., 2022, Thorac Cancer
14. Clinical outcomes and neuroendocrine features of transformed versus primary small-cell lung cancer — Chen et al., 2025, Lung Cancer
15. Pathological extranodal extension in head and neck cancer: A prognostic biomarker with therapeutic ramifications and diagnostic pitfalls — Chohan et al., 2025, Pathology - Research and Practice
16. Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer — Crespi et al., 2025, Lung Cancer
17. PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma — Deng et al., 2020, Cancer Management and Research
18. Association between pathologic response and survival after neoadjuvant therapy in lung cancer — Deutsch et al., 2024, Nature Medicine
19. New response evaluation criteria in solid tumours Revised RECIST guideline (version 1.1) — Eisenhauer et al., 2009, European Journal of Cancer
20. Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean? — Ferrara et al., 2019, Journal of Thoracic Oncology
21. Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study — Paul Wheatley-Price, Vishal Navani, Aliyah Pabani, Bertrand Routy, Stephanie Snow, Marie-Hélène Denault, YongJin Kim, Iqra Syed, Natalie Devost, Daphne Hui, Rana A. Qadeer, Paul Arora, Russanthy Velummailum, Aaron Springford, Chelsea McKibbon, Cheryl Ho, 2025, Lung Cancer
22. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer — Forde et al., 2022, New England Journal of Medicine
23. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer — Forde et al., 2025, New England Journal of Medicine
24. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer — Gandhi et al., 2018, New England Journal of Medicine
25. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab — Gao et al., 2022, Lung Cancer
26. Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis — Ruolin Gao, ZhenXiang Li, Jie Huang, Jun Zhao, Yan Wang, Qinxiang Guo, Guangchuan Deng, Hua Bai, Xu Yang, Jianchun Duan, Zhijie Wang, Yuyan Wang, Jingjing Wang, Jiachen Xu, Rui Wan, Boyang Sun, Kailun Fei, Zixiao Ma, Jia Zhong, Jie Wang, 2026, Lung Cancer
27. Pembrolizumab for the treatment of non-small-cell lung cancer — Garon et al., 2015, New England Journal of Medicine
28. Pulmonary toxicity of immune checkpoint immunotherapy — Ghanbar and Suresh, 2024, J Clin Invest
29. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer — Goldstraw et al., 2016, Journal of Thoracic Oncology
30. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer — Rami S. Vanguri, Jia Luo, Andrew T. Aukerman, Jacklynn V. Egger, Christopher J. Fong, Natally Horvat, Andrew Pagano, Jose de Arimateia Batista Araujo-Filho, Luke Geneslaw, Hira Rizvi, Ramon Sosa, Kevin M. Boehm, Soo-Ryum Yang, Francis M. Bodd, Katia Ventura, Travis J. Hollmann, Michelle S. Ginsberg, Jianjiong Gao, MSK MIND Consortium, Matthew D. Hellmann, Jennifer L. Sauter, Sohrab P. Shah, 2022, Nature Cancer
31. Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials — Guerrera et al., 2025, Lung Cancer
32. Hallmarks of Cancer: New Dimensions — D. Hanahan, 2022, Cancer Discovery
33. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer — Haque et al., 2022, Acta Oncologica
34. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer — Haratani et al., 2024, British Journal of Cancer
35. Angiogenic heterogeneity in head and neck squamous cell carcinoma biological and therapeutic implications — Hasina et al., 2008, Lab Invest
36. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden — Hellmann et al., 2018, The New England Journal of Medicine
37. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC — Herbst et al., 2020, The New England Journal of Medicine
38. PD-L1 Immunohistochemistry Assays for Lung Cancer Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project — Hirsch et al., 2017, Journal of Thoracic Oncology
39. Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I-IIIA non-small cell lung cancer — Huyuk et al., 2023, Histopathology
40. Radiologic Extranodal Extension of Metastatic Lymph Nodes in Patients With Non-Small Cell Lung Cancer: Prognostic Utility and Diagnostic Performance — Jang et al., 2023, American Journal of Roentgenology
41. Radiologic Extranodal Extension of Metastatic Lymph Nodes in Patients With Non–Small Cell Lung Cancer: Prognostic Utility and Diagnostic Performance — Jang et al., 2023, American Journal of Roentgenology
42. Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot — Janjigian et al., 2021, Cancer Cell
43. JOURNAL CLUB Doubling Time of Thymic Epithelial Tumors Correlates With World Health Organization Histopathologic Classification — Jeong et al., 2017, AJR: American Journal of Roentgenology
44. Effect of Perfluorobutane Microbubbles on Radiofrequency Ablation for Hepatocellular Carcinoma Suppression of Steam Popping and Its Clinical Implication — Jeong et al., 2020, Korean J Radiol
45. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer — Jung et al., 2020, Lung Cancer
46. Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial — Jung et al., 2024, Journal of Breast Cancer
47. The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer — Kang et al., 2022, Cancer Research and Treatment
48. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis — Kim et al., 2019, The Korean Journal of Internal Medicine
49. Clinical Outcomes of Pencil Beam Scanning Proton Therapy in Locally Advanced Non-Small Cell Lung Cancer Propensity Score Analysis — Kim et al., 2021, Cancers
50. Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer a systematic review — Koomen et al., 2020, Histopathology
51. Mengting Shi, MD, a,b,c,d Jiya Sun, PhD, f Shen Zhao, MD, a,b,c Gang Chen, MD, a,b,c — Dongchen Sun, Jiaqing Liu, Huaqiang Zhou, Mengting Shi, Jiya Sun, Shen Zhao, Gang Chen, Yaxiong Zhang, Ting Zhou, Yuxiang Ma, Yuanyuan Zhao, Wenfeng Fang, Hongyun Zhao, Yan Huang, Yunpeng Yang, Li Zhang, 2022, Journal of Thoracic Oncology
52. Surgical Attrition After Neoadjuvant Chemoimmunotherapy for Stage II–III Non–Small Cell Lung Cancer: A Real-World Experience and Predictors — Lee et al., 2026, Lung Cancer
53. Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer — Leshem et al., 2023, Cancer
54. Interpretable multimodal deep learning for time-resolved survival prediction after hepatocellular carcinoma resection — Li et al., 2026, npj Digital Medicine
55. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends — Licker et al., 2006, The Annals of Thoracic Surgery
56. Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis — Liu et al., 2021, Journal of Thoracic Oncology
57. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB–IIIB lung squamous cell carcinoma — Liu et al., 2024, Scientific Reports
58. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition — Loi et al., 2021, Annals of Oncology
59. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC — Lu et al., 2024, The New England Journal of Medicine
60. 18F FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal — Masse et al., 2024, European Journal of Nuclear Medicine and Molecular Imaging
61. Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC — Mazzaschi et al., 2025, Clinical Cancer Research
62. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer — Mooradian et al., 2024, JAMA Network Open
63. Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA) A Nationwide, Real-World Study — Moore et al., 2023, Curr. Oncol.
64. Brief Report Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC A Post Hoc Subgroup Analysis From PACIFIC — Naidoo et al., 2023, Journal of Thoracic Oncology
65. Tissue adequacy and safety of percutaneous transthoracic needle biopsy for molecular analysis in non-small cell lung cancer: a systematic review and meta-analysis — Nam et al., 2021, Korean Journal of Radiology
66. Obesity and survival in advanced non-small cell lung cancer patients treated with chemotherapy, immunotherapy, or chemoimmunotherapy: a multicenter cohort study — Nie et al., 2024, BMC Medicine
67. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells — Noman et al., 2012, Cancer Research
68. Identification and validation of PCDHGA12 and PRRX1 methylation for detecting lung cancer in bronchial washing sample — Oh et al., 2024, ONCOLOGY LETTERS
69. Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-GlassLepidic Nodules — Park et al., 2018, Journal of Thoracic Oncology
70. Lung Cancer in Korea — Park et al., 2021, Journal of Thoracic Oncology
71. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer — Park et al., 2022, Journal of Clinical Oncology
72. Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy PACIFIC-KR — Park et al., 2023, Journal of Thoracic Oncology
73. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial — Paz-Ares et al., 2020, Annals of Oncology
74. Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer — Pennock et al., 2023, Clinical and Translational Radiation Oncology
75. Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial — Potter et al., 2023, The Annals of Thoracic Surgery
76. Cancer-induced systemic pre-conditioning of distant organs: building a niche for metastatic cells — Rabas et al., 2024, Nature Reviews Cancer
77. Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis — Rajaram et al., 2024, Chest
78. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma — Reiniger et al., 2019, Acta Oncologica
79. Early and locally advanced non-small-cell lung cancer an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy — Remon et al., 2021, Annals of Oncology
80. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma — Reuben et al., 2017, npj Genomic Medicine
81. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology — Riely et al., 2024, Journal of the National Comprehensive Cancer Network
82. Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology — Riely et al., 2026, Journal of the National Comprehensive Cancer Network
83. CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC — Rocha et al., 2018, Journal of Thoracic Oncology
84. Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy — Saal et al., 2025, JAMA Oncology
85. Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer — Satoshi Saito, Takanori Abe, Nao Kobayashi, Tomomi Aoshika, Yasuhiro Ryuno, Mitsunobu Igari, Ryuta Hirai, Yu Kumazaki, Yu Miura, Kyoichi Kaira, Hiroshi Kagamu, Shin-ei Noda, Shingo Kato, 2020, Clinical and Translational Radiation Oncology
86. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON) — Go Saito, Yuko Oya, Yoshihiko Taniguchi, Hayato Kawachi, Fujimoto Daichi, Hirotaka Matsumoto, Shunichiro Iwasawa, Hidekazu Suzuki, Takayuki Niitsu, Eisaku Miyauchi, Takashi Yokoi, Toshihide Yokoyama, Takeshi Uenami, Yoshihiko Sakata, Daisuke Arai, Asuka Okada, Kenji Nagata, Shunsuke Teraoka, Masaki Kokubo, 2021, Lung Cancer
87. Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC — Shaverdian et al., 2021, JTO Clinical and Research Reports
88. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study — She et al., 2022, EBioMedicine
89. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) — Shi et al., 2014, Journal of Thoracic Oncology
90. Which definition of a central tumour is more predictive of occult mediastinal metastasis in nonsmall cell lung cancer patients with radiological N0 disease? — Shin et al., 2019, European Respiratory Journal
91. Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study — Shoshihara et al., 2025, Lung Cancer
92. Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis — Sorin et al., 2024, JAMA Oncology
93. Five-Year Survival Outcomes From the PACIFIC Trial Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer — Spigel et al., 2022, J Clin Oncol
94. Chemo-Radio-Immunotherapy for NSCLC III ESRATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate — Stana et al., 2023, Cancers
95. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site — Subramanian et al., 2013, Journal of Thoracic Oncology
96. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer — Sugimoto et al., 2024, Scientific Reports
97. Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer — Sumitomo et al., 2022, Oncology Reports
98. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries — Sung et al., 2021, CA: A Cancer Journal for Clinicians
99. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non – small cell lung cancer: A multicenter retrospective cohort study — Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, Yukari Uemura, Eisaku Miyauchi, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Keiichi Jingu, Hisatoshi Sugiura, 2022, Clinical and Translational Radiation Oncology
100. Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC A Real-World Analysis Using a Nationwide Claims Database in Japan — Takeda et al., 2026, Clinical Lung Cancer
101. Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC A Real-World Analysis Using a Nationwide Claims Database in Japan — Takeda et al., 2026, Clinical Lung Cancer
102. Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab — Topp et al., 2021, Annals of Oncology
103. Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer — Tran et al., 2026, Journal for ImmunoTherapy of Cancer
104. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC — Tsuboi et al., 2023, The New England Journal of Medicine
105. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy — Wang et al., 2019, Nature Communications
106. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis — Yu Wang, Tao Zhang, Yilin Huang, Wei Li, Jingjing Zhao, Yin Yang, Canjun Li, Luhua Wang, Nan Bi, 2022, Int J Radiation Oncol Biol Phys
107. Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer — Wang et al., 2023, Frontiers in Oncology
108. Immune tolerance in transplantation — Wekerle, 2017, Clinical and Experimental Immunology
109. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer — Wu et al., 2020, The New England Journal of Medicine
110. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-gamma signaling and tumor-infiltrating lymphocytes — Wu et al., 2021, Journal of Hematology & Oncology
111. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society — Takeshi Johkoh, Kyung Soo Lee, Mizuki Nishino, William D. Travis, Jay H. Ryu, Ho Yun Lee, Christopher J. Ryerson, Tomás Franquet, Alexander A. Bankier, Kevin K. Brown, Jin Mo Goo, Hans-Ulrich Kauczor, David A. Lynch, Andrew G. Nicholson, Luca Richeldi, Cornelia M. Schaefer-Prokop, Johny Verschakelen, Suhail Raoof, Geoffrey D. Rubin, Charles Powell, Yoshikazu Inoue, Hiroto Hatabu, 2011, Radiology
112. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment — Xiong et al., 2019, Cancer Research
113. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer — Xu et al., 2022, Radiotherapy and Oncology
114. Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World) — Yang et al., 2024, The Journal of Thoracic and Cardiovascular Surgery
115. Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation — Zhang et al., 2025, Journal for ImmunoTherapy of Cancer
116. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis — Zhou et al., 2024, JAMA Network Open
117. Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial — Ting Zhou, Huaqiang Zhou, Fangfang Gao, Weineng Feng, Wei Jiang, Lu Huang, Feifei Zhao, Lili Chen, Mei Ji, Junfei Zhu, Yong Fang, Peirui Chen, Peng Wang, Jingxun Wu, Li Zhuang, Xiting Liu, Meiyu Deng, Guixiang Weng, Jibin Li, Chunyan Yang, Hongyun Zhao, Yunpeng Yang, Li Zhang, 2026, JAMA